First Light Asset Management LLC Sells 23,038 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

First Light Asset Management LLC lowered its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 5.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 383,310 shares of the company's stock after selling 23,038 shares during the period. Kymera Therapeutics comprises about 1.5% of First Light Asset Management LLC's portfolio, making the stock its 21st biggest position. First Light Asset Management LLC owned about 0.59% of Kymera Therapeutics worth $15,421,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Wellington Management Group LLP increased its stake in shares of Kymera Therapeutics by 14.9% in the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock valued at $213,514,000 after buying an additional 688,967 shares during the period. Avoro Capital Advisors LLC increased its position in Kymera Therapeutics by 14.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock valued at $207,184,000 after acquiring an additional 650,000 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Kymera Therapeutics by 3.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company's stock valued at $276,395,000 after acquiring an additional 224,859 shares during the last quarter. Foresite Capital Management VI LLC acquired a new position in shares of Kymera Therapeutics during the fourth quarter worth $5,887,000. Finally, Vanguard Group Inc. grew its stake in shares of Kymera Therapeutics by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company's stock worth $196,617,000 after purchasing an additional 133,546 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Stephens reaffirmed an "overweight" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. HC Wainwright raised their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Finally, Citigroup initiated coverage on Kymera Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $52.00 target price on the stock. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $56.36.

Kymera Therapeutics Stock Up 2.1 %

NASDAQ:KYMR traded up $0.73 on Friday, hitting $35.28. The stock had a trading volume of 640,377 shares, compared to its average volume of 556,208. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27. The business's fifty day moving average is $29.66 and its 200 day moving average is $38.32. The company has a market cap of $2.29 billion, a PE ratio of -15.08 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Ellen Chiniara sold 2,241 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the sale, the insider now owns 80,085 shares in the company, valued at approximately $2,438,588.25. This represents a 2.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the transaction, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,659 shares of company stock worth $324,567 in the last quarter. Insiders own 15.82% of the company's stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.